ImmuPharma (IMM) Share Price, News & Analysis

Company Overview

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Key Stats

• Today's Range: 4.12 to 4.69
• 50-Day Range: 1.05 to 5.90
• 52-Week Range: 0.82 to 7.40
• Volume: 2.63 million shs
• Average Volume: 17.53 million shs
• Market Capitalization: £17.85 million
• P/E Ratio: N/A
• Dividend Yield: 0.77%
• Price Target: N/A
• Consensus Rating: N/A

IMM Stock Analysis - Frequently Asked Questions

How have IMM shares performed this year?

ImmuPharma's stock was trading at GBX 1.18 at the start of the year. Since then, IMM stock has increased by 256.5% and is now trading at GBX 4.20.
View the best growth stocks for 2025 here.

How were ImmuPharma's earnings last quarter?

ImmuPharma plc (LON:IMM) issued its quarterly earnings results on Wednesday, September, 30th. The company reported ($1.69) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative trailing twelve-month return on equity of 131.41%.

How do I buy shares of ImmuPharma?

Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of ImmuPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuPharma investors own include Castleton Technology (CTP), 4D pharma (DDDD), MOTIF BIO PLC/S (MTFB), Nikola (NKLA), Thor Energy (THR), Aminex (AEX) and GSK (GSK).

Company Calendar

• Last Earnings: 9/30/2020
• Today: 2/22/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:IMM
• CUSIP: N/A
• CIK: N/A
• Web: www.immupharma.org
• Phone: +44-20-71524080
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-2,509,806.21
• Net Margins: 3,519.56%
• Pretax Margin: N/A
• Return on Equity: -131.41%
• Return on Assets: -43.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.60
• Quick Ratio: 1.03

Sales & Book Value

• Annual Sales: £-71,310.29
• Price / Sales: -250.37
• Cash Flow: GBX 0.20 per share
• Price / Cash Flow: 20.50
• Book Value: GBX 0.65 per share
• Price / Book: 6.51

Miscellaneous

• Outstanding Shares: 425,094,500
• Free Float: N/A
• Market Cap: £17.85 million
• Optionable: Not Optionable
• Beta: 1.53